Access cutting-edge locally advanced or metastatic solid tumor harboring an ntrk gene fusion treatment through this clinical trial at a research site in Santa Monica. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Santa Monica location
Preparing your pre-screening questions…
Access locally advanced or metastatic solid tumor harboring an ntrk gene fusion specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related locally advanced or metastatic solid tumor harboring an ntrk gene fusion treatment provided free
Check if you qualify for this locally advanced or metastatic solid tumor harboring an ntrk gene fusion clinical trial in Santa Monica, CA
No-Cost Study Care
Local to Santa Monica
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.
Sponsor: Bayer
Yes, this clinical trial (NCT04142437) has an active research site in Santa Monica, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for locally advanced or metastatic solid tumor harboring an ntrk gene fusion treatment options in Santa Monica, CA, this clinical trial (NCT04142437) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Santa Monica research site is actively enrolling participants for this clinical trial. You'll receive care from experienced locally advanced or metastatic solid tumor harboring an ntrk gene fusion specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all locally advanced or metastatic solid tumor harboring an ntrk gene fusion clinical trials near you to find additional studies recruiting in your area.
See all leukemia clinical trials recruiting in Santa Monica — not just this study.
Browse Leukemia Trials in Santa Monica →